Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-blind, Placebo-controlled, Randomised Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

NCT02804815 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT02804815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02804815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-blind, Placebo-controlled, Randomised Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
Lead sponsor
University College, London
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 31, 2015
Completion date
October 31, 2026
Enrollment
11,000 (estimated)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cancer, colorectal cancer, gastro-oesophageal cancer, prostate cancer